Article ; Online: Inhibition of murine colorectal cancer metastasis by targeting M2-TAM through STAT3/NF-kB/AKT signaling using macrophage 1-derived extracellular vesicles loaded with oxaliplatin, retinoic acid, and Libidibia ferrea.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
2023 Volume 168, Page(s) 115663
Abstract: Colorectal cancer is still unmanageable despite advances in target therapy. However, extracellular vesicles (EVs) have shown potential in nanomedicine as drug delivery systems, especially for modulating the immune cells in the tumor microenvironment (TME) ...
Abstract | Colorectal cancer is still unmanageable despite advances in target therapy. However, extracellular vesicles (EVs) have shown potential in nanomedicine as drug delivery systems, especially for modulating the immune cells in the tumor microenvironment (TME). In this study, M1 Macrophage EVs (M1EVs) were used as nanocarriers of oxaliplatin (M1EV1) associated with retinoic acid (M1EV2) and Libidibia ferrea (M1EV3), alone or in combination (M1EV4) to evaluate their antiproliferative and immunomodulatory potential on CT-26 and MC-38 colorectal cancer cell lines and prevent metastasis in mice of allograft and peritoneal colorectal cancer models. Tumors were evaluated by qRT-PCR and immunohistochemistry. The cell death profile and epithelial-mesenchymal transition process (EMT) were analyzed in vitro in colorectal cancer cell lines. Polarization of murine macrophages (RAW264.7 cells) was also carried out. M1EV2 and M1EV3 used alone or particularly M1EV4 downregulated the tumor progression by TME immunomodulation, leading to a decrease in primary tumor size and metastasis in the peritoneum, liver, and lungs. STAT3, NF-kB, and AKT were the major genes downregulated by of M1EV systems. Tumor-associated macrophages (TAMs) shifted from an M2 phenotype (CD163) to an M1 phenotype (CD68) reducing levels of IL-10, TGF-β and CCL22. Furthermore, malignant cells showed overexpression of FADD, APAF-1, caspase-3, and E-cadherin, and decreased expression of MDR1, survivin, vimentin, and PD-L1 after treatment with systems of M1EVs. The study shows that EVs from M1 antitumor macrophages can transport drugs and enhance their immunomodulatory and antitumor activity by modulating pathways associated with cell proliferation, migration, survival, and drug resistance. |
---|---|
MeSH term(s) | Animals ; Mice ; Cell Line, Tumor ; Colorectal Neoplasms/pathology ; Extracellular Vesicles/metabolism ; Macrophages/metabolism ; NF-kappa B/metabolism ; Oxaliplatin/pharmacology ; Oxaliplatin/therapeutic use ; Proto-Oncogene Proteins c-akt/metabolism ; Tretinoin ; Tumor Microenvironment |
Chemical Substances | NF-kappa B ; Oxaliplatin (04ZR38536J) ; Proto-Oncogene Proteins c-akt (EC 2.7.11.1) ; Tretinoin (5688UTC01R) |
Language | English |
Publishing date | 2023-10-11 |
Publishing country | France |
Document type | Journal Article |
ZDB-ID | 392415-4 |
ISSN | 1950-6007 ; 0753-3322 ; 0300-0893 |
ISSN (online) | 1950-6007 |
ISSN | 0753-3322 ; 0300-0893 |
DOI | 10.1016/j.biopha.2023.115663 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Ud II Zs.198: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.